OBA Information Technology & Intellectual Property LAW PROGRAM | Original Program Date: February 26, 2018

In September 2017, the Canadian government made substantial changes to the Patented Medicines (Notice of Compliance) Regulations (PM(NOC)), governing pharmaceutical patent litigation, as required under the Canada-European Union Comprehensive Economic and Trade Agreement (CETA).  Join us to explore the implications of these amendments for both innovative and generic pharmaceutical companies, including:

• The change from an application-based proceeding to an action-based proceeding
• New early disclosure requirements
• Expansion of section 8 damages, and other new remedies
• Shifting of the burden of proof

Get up to speed on what these changes mean for your practice, and gather valuable insights on the best process for timely resolution of PM(NOC) litigation under this new regime.

PROGRAM SPEAKERS

Keith Aguilera, Legal Counsel, GSK Canada
Carol Hitchman, Counsel, Sprigings Intellectual Property Law
Jordan Scopa, Partner, Goodmans LLP
Kristin Wall, Partner, Norton Rose Fulbright Canada LLP

PROGRAM CHAIR

Daniel Daniele, Norton Rose Fulbright Canada LLP